Related references
Note: Only part of the references are listed.Factors that Control the Circulation Time of Nanoparticles in Blood: Challenges, Solutions and Future Prospects
Jin-Wook Yoo et al.
CURRENT PHARMACEUTICAL DESIGN (2010)
Protein aggregation-Pathways and influencing factors
Wei Wang et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2010)
Sizing Nanomatter in Biological Fluids by Fluorescence Single Particle Tracking
Kevin Braeckmans et al.
NANO LETTERS (2010)
Critical Evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the Measurement of Nanoparticles and Protein Aggregates
Vasco Filipe et al.
PHARMACEUTICAL RESEARCH (2010)
A therapeutic antibody and its antigen form different complexes in serum than in phosphate-buffered saline: A study by analytical ultracentrifugation
Barthelemy Demeule et al.
ANALYTICAL BIOCHEMISTRY (2009)
A Critical Review of Methods for Size Characterization of Non-Particulate Protein Aggregates
John S. Philo
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2009)
Structural properties of monoclonal antibody aggregates induced by freeze-thawing and thermal stress
Andrea Hawe et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2009)
Quantitation of Protein Particles in Parenteral Solutions Using Micro-Flow Imaging
Chi-Ting Huang et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2009)
Protein Aggregation: Pathways, Induction Factors and Analysis
Hanns-Christian Mahler et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2009)
Overlooking Subvisible Particles in Therapeutic Protein Products: Gaps That May Compromise Product Quality
John F. Carpenter et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2009)
Effects of protein aggregates: An immunologic perspective
Amy S. Rosenberg
AAPS JOURNAL (2006)
Protein aggregation and bioprocessing
Mary E. M. Cromwell et al.
AAPS JOURNAL (2006)
Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b
S Hermeling et al.
PHARMACEUTICAL RESEARCH (2005)
Structure and conformation of intramolecularly cross-linked collagen
R Usha et al.
COLLOIDS AND SURFACES B-BIOINTERFACES (2005)
The use of asymmetrical flow field-flow fractionation in pharmaceutics and biopharmaceutics
W Fraunhofer et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2004)
Bioequivalence and the immunogenicity of biopharmaceuticals
H Schellekens
NATURE REVIEWS DRUG DISCOVERY (2002)
Lyophilization and development of solid protein pharmaceuticals
W Wang
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2000)
Nanoparticles with decreasing surface hydrophobicities:: influence on plasma protein adsorption
A Gessner et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2000)
Share Paper
